78
Participants
Start Date
November 30, 2013
Primary Completion Date
December 31, 2018
Study Completion Date
July 1, 2019
Carfilzomib
20/36 \* mg/m\^2 stepped up dosing, IV infusion (over 30 min), on days 1, 2, 8, 9, 15 and 16 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
Irinotecan
125 mg/m\^2, IV infusion (over 90 min), on days 1, 8, 15 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
Norton Cancer Institute, Louisville
University of Kentucky Markey Cancer Center, Lexington
Washington University School of Medicine, St Louis
University of Texas Medical Branch at Galveston, Galveston
Cancer Treatment Centers of America, Western Regional Medical Center, Goodyear
Virginia Mason Cancer Institute, Seattle
"Providence Portland Medical Center , Earle A. Chiles Research Institute"
"Aurora Research Institute , Aurora Cancer Care"
Lucille P. Markey Cancer Center at University of Kentucky
OTHER
Washington University School of Medicine
OTHER
Cancer Research and Biostatistics Clinical Trials Consortium
NETWORK